Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Douglas Taylor (), Ankur Pandya, David Thompson, Paula Chu, Jennifer Graff, James Shepherd, Nanette Wenger, Heiner Greten, Rafael Carmena, Michael Drummond and Milton Weinstein

The European Journal of Health Economics, 2009, vol. 10, issue 3, 255-265

Keywords: Cardiovascular disease; Cholesterol lowering; Cost-effectiveness; Decision analysis; Markov model; Secondary prevention; Statin therapy; I11 (search for similar items in EconPapers)
Date: 2009
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-008-0126-1 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:10:y:2009:i:3:p:255-265

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-008-0126-1

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().